Reviews/Psoriasis Psoriatic Arthritis/Biologics reduce psoriasis cardiovascular disease risk
Psa CVD · PSA-CVD-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Several separate groups of psoriasis patients, followed in the US, Korea, Spain, and Israel, had fewer heart attacks and other cardiovascular events when treated with biologic drugs than when treated with older pills taken by mouth [1][2][3][5]. Imaging of the arteries added support by showing that biologics shrank fatty plaque [7]. But every one of these studies simply watched patients who were already on one treatment or the other, rather than assigning treatment at random, so healthier patients may have been the ones getting biologics in the first place. Two findings pull against a simple 'biologics are better' story: a study focused on heart attacks found no real difference between a biologic and methotrexate [8], and one oral drug, apremilast, looked protective on its own [6]. The panel therefore treated the direction of the evidence as real and repeatedly seen, while noting it cannot rule out that sicker-versus-healthier patient selection is doing much of the work.
Five independent psoriasis cohorts report fewer cardiovascular events with biologics than with oral systemic therapy across hard endpoints: any CVD and MACE in a large cohort [1], cardiovascular events versus methotrexate [2], MACE versus classic antipsoriatics or apremilast [3], and MACE incidence far lower than methotrexate, cyclosporine, and mixed conventional agents in a nationwide Korean cohort [5]. A mechanistic imaging study adds a surrogate, showing reduced non-calcified coronary plaque burden with biologic therapy [7]. The signal is consistent in direction and reproduced across different populations and endpoints. All of this evidence is observational. The contested point: The evidence divides on whether the biologic-over-oral ordering is uniform: the cleanest same-outcome head-to-head found no significant difference between TNF inhibitors and methotrexate for myocardial infarction [8], and one oral agent (apremilast, IRR 0.17) was itself protective — lower than the IL-17 inhibitor (IRR 0.43) — in the same registry [6]. The deeper contest is whether the roughly consistent hazard reduction reflects a true drug effect or confounding by indication that no observational study here can exclude.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Every included study is observational; confounding by indication and healthy-user bias (biologics gated by cost, prior-failure, and cardiac screening) plausibly explains much of the ~40% hazard reduction and cannot be excluded.
The cleanest same-outcome head-to-head, [8], reports no significant difference between TNF inhibitor and methotrexate cohorts for MI — a null against the claim's exact comparator.
Where it remains uncertain. A study of myocardial infarction found no significant difference between TNF inhibitor and methotrexate cohorts [8], and apremilast, an oral agent, was itself protective (IRR 0.17) [6].
Aleatory
Absolute event rates are low (e.g. MACE 3.5 vs 12.1 per 1000 person-years [5]; 1.45% vs 4.09% by 12 months [2]), so chance variation in small numbers of events contributes to the spread of hazard estimates across cohorts.
Epistemic
The corpus contains only cohort and registry studies; no trial randomises biologic versus oral systemic therapy, leaving true causal effect on events unmeasured.
Inferential
Inferring event reduction from the plaque-burden finding [7] requires an unproven surrogate-to-outcome link within this corpus.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest direct biologic-vs-oral psoriasis comparison; significant CVD and MACE reduction.
“The biologic cohort had attenuated risk of any CVDs (HR 0.621; 95% CI 0.571, 0.676) and major adverse cardiac events (HR 0.697; 0.614, 0.792).”
Panel auditInternal validity: medium · scope of inference: Psoriasis patients on biologics (TNF, IL-17, IL-23) versus non-biologic oral therapy, cardiovascular events over 5 years.Key limitations: retrospective design · no confounder adjustment described in abstract · sample size not reported
Head-to-head TNFi vs an oral systemic (methotrexate) showing reduced CV hazard.
“TNFi users had overall lower cardiovascular event hazards than methotrexate users (hazard ratio 0.55; P < .01).”
Panel auditInternal validity: medium · scope of inference: Psoriasis patients on TNF inhibitors versus methotrexate, cardiovascular events at 12 months.Key limitations: single oral comparator (methotrexate only) · sample size not reported · no confounder adjustment described
Propensity-matched evidence that oral systemics carry higher MACE risk than biologics.
“MACE risk was also higher with classic antipsoriatics or apremilast (HR 1.66).”
Panel auditInternal validity: medium · scope of inference: Psoriasis patients on biologics versus classic antipsoriatic drugs or apremilast, death and cardiovascular disease.Key limitations: no confidence intervals or p-values in abstract · sample size not reported · significance of MACE HR not stated
Cardiovascular event risk was significantly reduced with anti-TNF and other biologic therapies, with confidence intervals excluding 1.
Panel auditInternal validity: medium · scope of inference: Inflammatory arthritis patients including psoriatic arthritis, major cardiovascular events with current biologic use.Key limitations: population is inflammatory arthritis, not moderate-to-severe psoriasis · oral comparator not specified · sample size not reported
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, reproduced observational support warrants Likely, but the absence of any randomised evidence, a null head-to-head, and unavoidable confounding by indication preclude a higher tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Absence of randomised event data. All support is observational, so the roughly consistent hazard reduction cannot be separated from selection of healthier patients into biologics. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised or target-trial-emulation design comparing biologic versus oral systemic therapy in moderate-to-severe psoriasis with adjudicated cardiovascular events.
Open question: Does biologic therapy reduce cardiovascular events versus oral systemic therapy once confounding by indication is removed? Why it is still open: Every corpus study is observational and cannot exclude that healthier patients receive biologics.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19